EP 53: Ai4 Podcast - Revolutionizing Healthcare: AI in Drug Discovery | Alex Zhavoronkov, Insilico Medicine

This episode was recorded live from the Ai4 conference podcast pavilion, Sam sat down with Alex Zhavoronkov, Founder & CEO of Insilico Medicine, about what it actually takes to turn AI-generated molecules into approved drugs. What's Covered: From Laughed-Out-of-the-Room to 33 Candidates — Alex pitched generative AI for drug design in 2015 and got dismissed. Today: 33 developmental candidates in six years, zero failed toxicity studies, and deals with Eli Lilly, Takeda, Servier, and SK Bio at a pace of nearly one per month. The Real Bottleneck — "It's not about a story. Many people in our field love to tell a story, but they don't have a single drug in the clinic discovered by AI." Alex's direct take on separating hype from results in AI drug discovery. A Lucky Breakthrough — The story of how Insilico stumbled onto a novel, non-opioid pain mechanism that outperformed morphine in animal testing — now targeting a $70 billion market. Why Abu Dhabi — Not for speed, but for geopolitical neutrality. Alex explains why Insilico built a 60-person AI lab in the UAE, and how two drugs now trace their origin to the Middle East for the first time in modern history. Quantum-Generated Drugs — A December 2025 Nature Biotechnology cover story: a molecule generated on a real IBM quantum computer, validated experimentally, with the University of Toronto. Pharmaceutical Superintelligence vs. AGI — Where Alex thinks AI drug discovery already stands, and why he draws a hard line between a useful scientific partner and the "conscious AI God" version of AGI. Key Quote: "In terms of pharmaceutical superintelligence, we're very close to being there.